Loading page...
Loading page...
This round is closed. The next round and similar open calls are listed below. Synced from the EU Funding & Tenders Portal on 16 November 2026.
This call is closed. These open or upcoming calls fund the closest work.
Based on projects the EU funded on the same subject in this programme.
VIROMARKERSVirus related biomarkers to improve management of chronic conditions
HORIZON-JU-IHI-2024-07-03-singe-stage · 2025 · Official record ↗
BRECISEBiomarker Research and Evaluation for Clinical Implementation and Supporting Systems Enhancement
HORIZON-JU-IHI-2024-07-03-singe-stage · 2025 · Official record ↗
LIVERAIMA Biomarker-Based Platform for Early Diagnosis of Chronic Liver Disease to Enable Personalized Therapy
HORIZON-JU-IHI-2022-03-01 · 2024 · Official record ↗
PRECISE-TBMProspective evaluation and refinement of novel biomarker-based point-of-care tests for the diagnosis of tuberculous meningitis in children
HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage · 2026 · Official record ↗
SAIFASerbian Artificial Intelligence Factory Antenna
HORIZON-JU-EUROHPC-2025-AIFA-01 · 2026 · Official record ↗
JUA KIVUJoint Understanding and Analysis of clade I monkeypox epidemiology, evolution and immunology in South Kivu
HORIZON-JU-GH-EDCTP3-2024-Mpox · 2024 · Official record ↗
INTERCEPTVerification and validation of a biomarker panel that identifies individuals at high risk to develop Crohn’s disease allowing INTERCEPTION of full-blown disease development
HORIZON-JU-IHI-2024-07-03-singe-stage · 2025 · Official record ↗
AFRICAI-RIA Pan-African Research Infrastructure for Collaborative Biomedical Imaging and Artificial Intelligence in Respiratory Care
HORIZON-JU-GH-EDCTP3-2024-01-06-two-stage · 2025 · Official record ↗
Each one links to its EU funding record and the partners it works with: a starting list for building a consortium.
The action under this topic is expected to achieve the following impacts:
Patients and citizens will benefit from improved medical practice and healthcare solutions, new targeted prevention strategies and ultimately healthier ageing.
The action will support EU policy and priorities including the European Health Data Space Regulation (EHDS) and the EU Artificial Intelligence Act, while contributing to European competitiveness in addressing one of society's major challenges.
The action under this topic must contribute to all of the following outcomes:
The global population is undergoing an unprecedented demographic shift, with the number of individuals aged 65 and older projected to double by 2050, presenting one of the most significant public health challenges of our time. The transition to an ageing society is accompanied by a parallel rise in the prevalence of chronic diseases, multimorbidity, and years lived in poor health, placing immense strain on healthcare systems worldwide [1]. Central to this phenomenon is the progressive decline of immune function with age which not only increases susceptibility to infections and malignancies, but also drives chronic low-grade inflammation, known as "inflammaging" [2].
The profound age-related changes to the immune system are collectively termed immunosenescence. These changes include thymic involution, reduced naive T-cell production, expansion of memory T-cells with limited repertoire diversity, increased inflammatory cytokine production (inflammaging), and broad dysregulation of innate immunity [3] [4]. In parallel, senescent cells accumulate and secrete SASP cytokines—such as IL‑6, IL‑1β, and TNF—which further amplify inflammaging and contribute directly to age‑related immune dysfunction [5] [6]. Concurrently, there is a rising incidence of immune-mediated diseases with initial onset in elderly populations, including late-onset rheumatoid arthritis [7], elderly-onset inflammatory bowel disease (IBD) [8], late-onset systemic lupus erythematosus (SLE) [9] and late-onset respiratory diseases [10] [11].
Critically, advanced age is associated with the increased incidence of autoimmune and inflammatory diseases [12]. Moreover, older adults exhibit heightened vulnerability to immune-mediated pathologies ranging from late-onset autoimmune disorders to vaccine hyporesponsiveness and impaired tissue repair [13] [14]. Despite the clear clinical burden, the mechanistic underpinnings of how ageing reshapes immune homeostasis and disease susceptibility, and concomitantly, of how diseases reshape the ageing-process and the immune system, remain incompletely understood. A comprehensive understanding of the bidirectional relationship between immune system dysfunction and the ageing process is therefore imperative to develop targeted interventions that can prevent, delay, or reverse age-associated immune diseases and ultimately extend health span.
Despite their clinical significance, elderly-onset immune diseases remain poorly understood compared to their younger adult-onset counterparts. Evidence suggests that they may represent distinct disease entities with unique pathogenic mechanisms, clinical presentations, and treatment responses [15] [16]. The intersection of immunosenescence with pathological immune dysregulation presents both challenges and opportunities for targeted interventions.
Industry, regulators, researchers, and other stakeholders should address the critical gap in our understanding of how ageing-related immune changes contribute to disease pathogenesis in the elderly. New evidence-based findings should help to elucidate the molecular drivers of both elderly-onset immune diseases as well as immune disease exacerbations during ageing. In addition, these findings should help to identify predictive biomarkers, leading to age-appropriate therapeutic and prevention strategies accounting for the unique immunological context of older patients, and ultimately reducing the socio-economic burden for society.
The action funded under this topic therefore aims to elucidate the key biological determinants that drive healthy ageing and immune‑mediated disease, with a particular focus on how age‑associated immune system remodelling shapes these outcomes.
Applicants are expected to address all of the following objectives of the topic in their proposal:
Understanding molecular and clinical differences between younger adult-onset and elderly-onset diseases: The focus of the action should be on immune-mediated diseases with a peak of onset in elderly patients, such as inflammatory bowel disease and respiratory diseases, and specifically directed to diseases with mainly elderly onset.
Therefore, in summary the proposal should cover the following immune-mediated diseases:
The focus and the combination of these disease types would limit the risk of dispersion but still reflect different organ systems and enable crucial cross-disease comparisons.
Identify drivers of elderly-onset immune diseases: Determine the specific cellular and molecular mechanisms that trigger immune dysregulation uniquely in elderly populations.
Characterise factors driving disease exacerbations with ageing: Investigate how age-related physiological changes influence disease progression and flare frequency/severity.
Evaluate biological age as a driver of disease: Distinguish chronological from biological ageing in disease pathogenesis and identify predictive biomarkers for onset and exacerbations, including the influence of comorbidities.
Discriminate the molecular phenotypes and associated patient characteristics between chronologically aged versus biologically aged adults and elderly-onset disease patients. Understand patient heterogeneity in elderly-onset disease, both in regard to treatment response and molecular signatures.
Define the relevance of immunosenescence on biological and chronological ageing and whether there is a causal link between age, senescence and chronic inflammatory diseases including treatment response.
Identify common immunosenescence signatures across elderly-onset immune diseases: Elucidate shared pathways that might represent universal therapeutic targets.
Evaluate how vaccination history can contribute to reducing disease onset and/or exacerbation in older populations. Moreover, assess the translatability of system serology or other immunological endpoints as senescence markers.
Pathway identification and validation: AI / machine learning (ML)-assisted identification of underlying biological pathways and biomarkers from the gathered datasets. Evaluation of the impact of ageing on treatment effectiveness. Assessment of the predictiveness of identified biomarkers in ageing populations independent of underlying chronic inflammatory diseases.
Applicants should envisage the following activities as part of the action funded under this topic:
1. Applicants are expected to define a strategy to assess age-related disease phenotypes and related biomarkers, incorporating a modelling perspective alongside AI-assisted data mining, appropriate statistical methodologies, and prioritisation approaches for the exploration of mechanisms of action (MoA).
2. Applicants should detail their methodological approach, including verification strategies and data collection procedures, providing preliminary data to show potential for success and strategies for mitigating the main methodological risks and limitations.
The action should leverage both the wealth of existing cohorts, as well as the data from a new targeted observational cohort, which is expected to be set up by the consortium, and to include appropriate age-ranges and disease onset groups. New and existing observational cohorts should be used to evaluate the impact of standard of care treatments on the chosen diseases to define a path forward towards precision medicine and understanding age-dependent impacts of therapy response.
The analysis of existing and new bio-specimens (peripheral blood mononuclear cells, white blood cells, stool, saliva, urine, diseased tissues and exhaled breath condensate) should allow for the conduct of deep molecular profiling of the targeted chronic inflammatory diseases across various age ranges with appropriate age-matched control groups.
The wealth of data (both existing as well as newly created via the observational cohort), including participants’ clinical characteristics and health records (e.g. disease, comorbidities, frailty assessment, vaccination and infection history) gathered through state-of-the-art methodologies and technologies will enable the comprehensive analysis of chronological ageing, biological ageing markers, and immune signatures through:
3. Applicants are expected to consider the potential regulatory impact of the results and, as relevant, develop a regulatory strategy and interaction plan for generating appropriate evidence as well as engaging with regulators in a timely manner. Additionally, applicants should anticipate engaging regional healthcare systems and authorities to prepare for clinical implementation and outcome acceptance when necessary.
4. Applicants should include in their proposal a strategy to ensure sustainability of the outputs of the project, including data and samples collected, beyond the funding period.
5. Applicants should leverage experience from the European research infrastructures (ERICs) already working on the areas mentioned in this call topic to avoid overlaps and increase the impact of results.
The action funded under this topic is expected to consider potential synergies with projects that work on the area of interest of this topic.
[1] Garmany A, Terzic A. et al. Longevity leap: mind the healthspan gap. NPJ Regen Med. (2021)
[2] Yousefzadeh, M.J., Zhu, Y. et al. An aged immune system drives senescence and ageing of solid organs. Nature (2021)
[3] Weyand, C.M., Goronzy, J.J. et al. Sustained immune youth risks autoimmune disease in the aging host. Nat Aging (2025)
[4] Li, X., Li, C., Zhang, W. et al. Inflammation and aging: signaling pathways and intervention therapies. Sig Transduct Target Ther. (2023)
[5] Soto-Gamez A., Quax J. W., Demaria M. Survival networks in senescent cells. Journal of Molecular Biology (2019)
[6] De Luca F., Camporeale V., Leccese G., et al. From Scenescent Cells to Systemic Inflammation Cells (2025)
[7] Zimba O, Kocyigit BF. et al. Late-onset rheumatoid arthritis: clinical features, diagnostic challenges, and treatment approaches. Rheumatol Int. (2025)
[8] Granot M, Haberman Y. et al. Elderly-Onset Inflammatory Bowel Disease Has Distinct Disease Characteristics and Treatment Patterns. United European Gastroenterol J. (2025)
[9] Mruthyunjaya, P., Ahmed, S., Botabekova, A. et al. Late-onset Systemic Lupus Erythematosus. Rheumatol Int. (2025)
[10] Turrin, M., et al. Differences Between Early- and Late-Onset Asthma: Role of Comorbidities in Symptom Control. The Journal of Allergy and Clinical Immunology: In Practice (2022)
[11] Patterson, K. C., et al. Interstitial Lung Disease in the Elderly. CHEST (2017)
[12] Terekhova M., Bohacova P., Artyomov M.N., Human immune aging. Immunity (2025)
[13] Hofer S.J., Rapp S., Klenermann P., Simon A.K. Understanding and improving vaccine efficacy in older adults. Nature Aging (2025)
[14] Xu A., Liu Y. et al Global burden of major chronic respiratory diseases among older adults … PlosOne (2025)
[15] Basu S, Ulbricht Y. and Rossol M. Healthy and premature aging of monocytes and macrophages. Front. Immunol. (2025)
[16] Li Y., Ma J. et. al. The research progress of biologics in elderly-onset rheumatoid arthritis (EORA). Front. Aging (2025)
1. Admissibility conditions: Proposal page limit and layout
described in Annex A and Annex E of the Horizon Europe Work Programme General Annexes.
Proposal page limits and layout: described in Part B of the Application Form available in the Submission System :
2. Eligible countries
described in Annex B of the Work Programme General Annexes.
A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon Europe projects. See the information in the Horizon Europe Programme Guide.
3. Other Eligibility Conditions
described in Annex B of the Work Programme General Annexes and in the ''Conditions of the Calls for proposals and Calls management rules'' section of the IHI JU Work Programme (WP)
4. Financial and operational capacity and exclusion
described in Annex C of the Work Programme General Annexes.
5a. Evaluation and award: Award criteria, scoring and thresholds
described in Annex D of the Work Programme General Annexes and in the ''Conditions of the Calls for proposals and Calls management rules'' section of the IHI JU Work Programme (WP)
5b. Evaluation and award: Submission and evaluation processes
described in Annex F of the Work Programme General Annexes and the Online Manual.
5c. Evaluation and award: Indicative timeline for evaluation and grant agreement
described in Annex F of the Work Programme General Annexes.
6. Legal and financial set-up of the grants
described in Annex G of the Work Programme General Annexes.
described in the ''Conditions of the Calls for proposals and Calls management rules'' section of the the IHI JU Work Programme (WP)
Where relevant, templates of the reference documents and associated guidance can be found on the IHI JU website.
Regarding the application forms for submitting proposals, the relevant templates and annexes are available to download in the submission system of the Funding and Tender Opportunities portal.
The IHI JU 13th Call for proposals full topics text is available here.
Application and evaluation forms and model grant agreement (MGA):
Application form templates — the application form specific to this call is available in the Submission System
Evaluation form (RIA Actions – single and two-stage Calls procedure)
IHI JU Evaluation form for Research and Innovation Actions
Proposal Templates Part A and Part B (RIA Actions – single and second stage of two-stage procedure)
1. For 1st stage of two-stage calls
Compulsory annex for Short proposals. The “type of participants” is an IHI specific annex related to Short proposals (first stage of two-stage calls). It can be found here. Instructions on how to fill in this template can be found here.
2. For 2nd stage of two-stage calls
a) Annex to the Budget and Type of participants
Compulsory annex for Full proposals, which complements the budget figures already included in the proposal budget in PART A. Its purpose is to correctly guide the consortium in providing IHI-specific budget items (e.g. IKOP, IKAA, FC PAID, FC RECEIVED) and to comply with IHI additional eligibility criteria (e.g. 45% industry contribution).
The excel document template can be found here.
Instructions on how to fill in the budget can be found here.
Instructions on how to fill the type of participants can be found here.
b) Annex: Declaration of in-kind contribution commitment
Compulsory annex for the second stage of two-stage calls and single-stage calls.
The word document template can be found here.
c) Annex: In-kind contributions to additional activities (IKAA)
Compulsory annex for the second stage of two-stage calls and single-stage calls and when the proposal includes IKAA.
The ‘’In-kind contributions to additional activities (IKAA)’’ is an IHI specific annex.
The excel template can be found here.
d) Annex: Essential information for clinical studies
Compulsory annex for the second stage of two-stage calls and single-stage calls which must be uploaded as a separate document in the submission system. If your proposal does not include clinical studies, please upload a statement declaring that your proposal does not include clinical studies.
The information on clinical studies annex can be found here.
d) Annex: Ethics
Optional annex for the second stage of two-stage calls and single-stage calls. Part A of the proposal includes an ethics self-assessment. However, if the proposal raises many serious ethical issues, the character count in Part A may not be enough for applicants to provide all the information needed. If this is the case for you, you should provide any additional information on the ethical aspects of your proposal in a separate document and upload it as an ethics annex. Note that there is no specific template for this annex.
3. Model Grant Agreements (MGA)
HE MGA
Additional documents:
Council Regulation (EU) 2021/2085 of 19 November 2021 establishing the Joint Undertakings under Horizon Europe and repealing Regulations (EC) No 219/2007, (EU) No 557/2014, (EU) No 558/2014, (EU) No 559/2014, (EU) No 560/2014, (EU) No 561/2014 and (EU) No 642/2014 (in short Single Basic Act ‘SBA’ or Council Regulation (EU) 2021/2085).
IHI JU Work Programme (WP)
Strategic Research and Innovation Agenda (SRIA)
IHI JU Guide for Applicants
IHI JU FAQs
Horizon Europe Reference Documents :
HE Main Work Programme 2026-2027 – General Annexes
HE Programme Guide
EU Financial Regulation 2024/2509
Rules for Legal Entity Validation, LEAR Appointment and Financial Capacity Assessment
EU Grants AGA — Annotated Model Grant Agreement
Funding & Tenders Portal Online Manual
Funding & Tenders Portal Terms and Conditions
Funding & Tenders Portal Privacy Statement
Confirm the current call documents and submission conditions with the funding authority.
View on EU portal ↗Source: EU Funding & Tenders Portal · synced 2026-11-16
A free account keeps your shortlist and sends deadline reminders. The EUACC connector brings this call, its FAQs, past winners and similar calls into Claude or ChatGPT, so you can check fit and draft with sources.